Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144)
Sammaiah Pallerla,
Shaunak D. Uplekar,
Ferenc Boldog,
James C. Paulson,
Sabyasachi Baboo,
John R. Yates III,
Wen‐Hsin Lee,
Gabriel Ozorowski,
Joel D. Allen,
Max Crispin,
Chris Cottrell,
Andrew B. Ward,
Varsha Sitaraman,
Tim Broderick,
Amber Costakes,
Nikolette McCombs,
Derek Ryan,
Leslie Wolfe,
Daniel Craig,
Kristen Syvertsen,
Albert E. Price,
Jon M. Steichen,
William R. Schief
Wiley ·
2026-10-21
· DOI 10.1002/bit.70409
⬢ Cited by: 0Crossref
The publisher did not provide an abstract — full text is available via the link below.
Sammaiah Pallerla, Shaunak D. Uplekar, Ferenc Boldog, James C. Paulson, Sabyasachi Baboo, John R. Yates III et al. Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144). // Biotechnology and Bioengineering. – 2026. – DOI: 10.1002/bit.70409. – URL: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bit.70409?af=R
Sammaiah Pallerla, Shaunak D. Uplekar, Ferenc Boldog, James C. Paulson, Sabyasachi Baboo, John R. Yates III, Wen‐Hsin Lee, Gabriel Ozorowski, Joel D. Allen, Max Crispin, Chris Cottrell, Andrew B. Ward, Varsha Sitaraman, Tim Broderick, Amber Costakes, Nikolette McCombs, Derek Ryan, Leslie Wolfe, Daniel Craig, Kristen Syvertsen, Albert E. Price, Jon M. Steichen, & William R. Schief (2026). Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144). Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70409
Sammaiah Pallerla, et al. “Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144).” Biotechnology and Bioengineering, 2026. doi:10.1002/bit.70409.
@article{Pallerla2026,
title = {Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144)},
author = {Pallerla, Sammaiah and Uplekar, Shaunak D. and Boldog, Ferenc and Paulson, James C. and Baboo, Sabyasachi and III, John R. Yates and Lee, Wen‐Hsin and Ozorowski, Gabriel and Allen, Joel D. and Crispin, Max and Cottrell, Chris and Ward, Andrew B. and Sitaraman, Varsha and Broderick, Tim and Costakes, Amber and McCombs, Nikolette and Ryan, Derek and Wolfe, Leslie and Craig, Daniel and Syvertsen, Kristen and Price, Albert E. and Steichen, Jon M. and Schief, William R.},
journal = {Biotechnology and Bioengineering},
year = {2026},
doi = {10.1002/bit.70409},
url = {https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bit.70409?af=R}
}